About Merck & Co Inc
- Industry: Pharmaceuticals
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.merck.com/
Frequently Asked Questions
What is the 52-week range for MRK?
The 52-week high is $156.92 and the 52-week low is $82.01.
What is the P/E ratio for MRK?
The Price to Earnings (P/E) ratio is 111.61.
What is the dividend yield for MRK?
The indicated annual dividend yield is 2.87%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 6.60%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 4.77%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.97.
Analyst Recommendation Trends
Wall Street analyst consensus for MRK over the last few months:
Latest MRK News
Merck (MRK) Reports Positive Phase 2b Tulisokibart Results In Hidradenitis Suppurativa
Merck (NYSE:MRK) reported positive Phase 2b results for tulisokibart in moderate to severe hidradenitis suppurativa on 1 October 2026. The investigational anti TL1A monoclonal antibody met its Phase 2b efficacy goals in patients with this chronic inflammatory skin condition. Merck stated that tulisokibart's Phase 2b data support advancing the program into Phase 3 trials in hidradenitis suppurativa. There is much more to Merck's story than the tulisokibart Phase 2b milestone in hidradenitis...
Dividend Champion, Contender, And Challenger Highlights: Week October 4
Track weekly dividend updates for Dividend Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend and pay dates. Read it here.
What's going on in today's session: dow jones movers
Curious about the top performers within the dow jones index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.
8 Of 11 Sectors Rise Friday As Growth Leads
Friday's regular session has eight sectors higher and three lower, with growth sectors holding two of the top three positions. The leaders are clustered, with less than a quarter-point separating the top three sectors.
How Has Pfizer's Story Changed?
Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.
These dow jones stocks are moving in today's session
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says
Merck's (MRK) data from a phase 2b study evaluating tulisokibart in hidradenitis suppurativa looks s
JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning
Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.
What Is The Options Market Telling Us About Eli Lilly Stock?
Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.
Why Citi Is Sounding the Alarm on Moderna Stock
The cancer pipeline gave Moderna's shares a rocket boost. Citi, however, just checked the stock’s price tag and wasn’t exactly impressed.
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Citigroup just told investors to sell Moderna and the stock responded by climbing 3%, raising one pointed question about whether pipeline optimism has fully broken free from Wall Street's valuation warnings.
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.
Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz
Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
RAHWAY, N.J., October 01, 2026--Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
Citi delivers major verdict after Moderna’s remarkable 703% run
Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.
Why Merck (MRK) Dipped More Than Broader Market Today
In the latest trading session, Merck (MRK) closed at $145.31, marking a -2.66% move from the previous day.
Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.
Top Analyst Reports for Apple, Microsoft & Broadcom
Apple, Microsoft and Broadcom face contrasting growth drivers and risks, from AI and cloud demand to capacity constraints and customer concentration.
Stay informed with the top movers within the dow jones index on Wednesday.
Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.
Was The Run In JNJ Stock Hiding In Plain Sight?
Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.
Merck Says Investigational Skin Therapy Shows Potential
Merck & Co Inc. (NYSE:MRK) on Wednesday presented initial results from its Phase 2b MK-7240-012 trial at the European Academy of Dermatology and Venereology (EADV) 2026 Congress. Phase 2b Trial Delivers Positive Results The study evaluated tulisokibart—an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A)—in patients with moderate to severe hidradenitis suppurativa. The trial met its primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR
Moderna, Cerebras, Jabil, HPE, Cal-Maine, Mattel, and More Stocks That Explain Today’s Market
Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.
2 Outstanding Dividend Stocks to Buy and Hold for a Decade
There is probably no dividend cut on the horizon for these healthcare companies.
Uncover the latest developments among dow jones stocks in today's session.
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Wednesday.
3 Healthcare Dividend Stocks Offering More Than Just Income
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.
Are You Overpaying For Pfizer Stock Versus Its Rivals?
Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter
Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.
What Is Merck Stock's Biggest Opportunity?
Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.
After Moderna's Dizzying Rally, It's Time To Sell, Says Analyst
After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares.
What's Going On With Moderna Stock on Wednesday?
Moderna stock dips as Juan Andres returns as COO, Jerh Collins retires, and the company expands its vaccine and cancer therapy portfolio.
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat
Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.
3 Cash-Producing Stocks with Open Questions
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Moderna, Concentrix, Boeing, HPE, Robinhood, Cal-Maine, and More Stocks That Explain Today’s Market
Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
RAHWAY, N.J., September 30, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS). These data will be presented in a Late-Breaking News
SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does.
SHCD is missing some of the healthiest dividend stocks.
Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatologyTulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HSMerck (NYSE:MRK), known
Personalis: The Wrong Side Of The Merger
Personalis shareholders remain exposed to downside in TEM shares while having limited ability to benefit from further TEM appreciation above $48.42. Learn more about PSNL stock here.
Merck Stock Slips 1.5% as $400 Million Buys KRAS Rights
The agreement can reach $2.13 billion, although SPR2015 remains a preclinical cancer candidate.
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers.
Which dow jones stocks are moving on Tuesday?
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Is Eli Lilly Stock a Good Fit For Your Portfolio Risk?
You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.
Prediction: Eli Lilly’s Next Growth Wave Could Surprise Investors
Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions. The outcome of that tension shapes whether shares have another 20% to climb or stall near today's levels.
Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree?
Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.
What Does Merck (MRK) Add To Its Oncology Pipeline With This KRAS Deal?
Merck (NYSE:MRK) entered an exclusive global license agreement with SciBrunch Therapeutics to develop oral KRAS G12D inhibitor SPR2015. The deal gives Merck worldwide rights to SPR2015, an investigational small molecule targeting a mutation linked to several solid tumors. SciBrunch will collaborate with Merck on early development activities for SPR2015, which is designed as an oral targeted oncology therapy. Merck's exclusive license for SPR2015, an oral KRAS G12D inhibitor, now needs...
Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year
Merck spent most of a decade trailing the S&P 500, then something unusual happened in a single year that changed the entire math. Whether that burst signals a new chapter or a one-time event comes down to a drug patent clock and a $14.8 billion bet on acquisitions.
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck
Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation.
AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space
Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
Inside the AstraZeneca Deal That Could Send Summit Therapeutics Stock Up 126%
The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.
Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors
BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.
Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion
Moderna (MRNA) valuation update: stock near bull-case range but central-case implies downside.
MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor
This bet comes amid the strong industry buzz around the approval of Revolution Medicines’ OS-doubling pancreatic cancer treatment, Rasonque.
Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $180
Scotiabank analyst Louise Chen maintains Merck & Co (NYSE:MRK) with a Sector Outperform and raises the price target from $155 to $180.
Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer
AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Small Molecule Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global small molecule drug discovery market was valued at US$61.5 billion in 2024 and is projected to reach US$100 billion by 2030, expanding at a compound annual g
Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical developmentThe milestone triggers a payment to Cyprumed under the companies’ existing collaboration agreement Innsbruck, Austria, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cyprumed GmbH, a dedicated oral drug delivery company specializing in innovative oral peptide formulations, today announced that MSD (tradename
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab
AstraZeneca invests $2 billion in Summit Therapeutics to combine cancer drugs ivonescimab and Sone-Ve.
Cyprumed's Oral Peptide Tablet Technology Enters Human Clinical Development As MSD Initiates Phase I Trial, Triggering Milestone Payment For Up To $493M From MSD
The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical developmentThe milestone
Merck (MRK) Withdrew a Cancer Filing. Is the Drug’s Promise Still Intact?
Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults whose extensive-stage small-cell lung cancer progressed during or after platinum-based chemotherapy. Following FDA discussions, the partners said the submitted evidence, including Phase 2 results, did not satisfy accelerated-approval requirements. The investment […]
Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job?
On September 24, Merck & Co., Inc. (NYSE:MRK) announced positive topline results from its pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig, a potentially first-in-class tri-specific Wnt pathway agonist, in adults with diabetic macular edema (DME). At 52 weeks, both the 0.5 mg and 0.8 mg doses met the primary endpoint by demonstrating non-inferiority to the […]
$85 Billion And Counting: JNJ Stock's Steady Cash-Return Habit
A healthcare giant sent a torrent of cash back to its owners, but the real story is what that money did, and did not, buy for the stock.
What Are Merck Stock Investors Overlooking?
If you own Merck (MRK) stock, the number to watch is the sales of one cancer drug family. KEYTRUDA family sales were $8.4 billion in the second quarter of 2026. That was about half of Merck's $16.6 billion in quarterly revenue. Management now expects KEYTRUDA’s U.S. growth to moderate, raising questions about whether the stock's recent run has fully priced in the transition.
Johnson & Johnson’s Next Growth Engine Is Taking Shape
Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull case or the headwinds win.
Merck’s Forward P/E Nearly Doubled to 17x in a Year. Here’s What Its Pipeline Must Deliver by 2030
Key Stats for Merck StockCurrent Price: $148. 74Target Price (Mid): ~$166Street Target: ~$154Potential Total Return: ~12%Annualized IRR: ~3% / yearWhat Happened?Daiichi Sankyo and Merck (MRK) withdrew their application for accelerated U.
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.
Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit
SOUTH SAN FRANCISCO, Calif., September 28, 2026--Mission Bio, the single-cell multiomics leader, today announced that Merck & Co. and Incyte will each present new data generated using Mission Bio’s Assay Services and Tapestri® Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit (World CDx), alongside a third presentation from Mission Bio featuring new clinical data in acute myeloid leukemia. Together, the presentations demonstrate the use of single-cell multiomics from
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.
Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug
Merck and Daiichi Sankyo voluntarily withdrew their FDA application for a lung cancer drug due to insufficient data, though trials continue.
CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
Merck (NYSE: MRK), known as MSD outside the United States and Canada, welcomes Ontario's decision to include CAPVAXIVE® in its publicly funded adult immunization program. This addition helps expand access to pneumococcal immunization for eligible older adults in Ontario.
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
RAHWAY, N.J., September 28, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. ("SciBrunch"), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.
Global Cell Line Generation Market Outlook, 2026-2032 - AI, CRISPR and Automation Fuel 10.86% CAGR, Driving the Market to USD 2.67 Billion as Thermo Fisher Scientific, Lonza, Merck and WuXi Biologics Advance Innovation
Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforce trainingDublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Cell Line Generation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global cell line generation market, which is projected to reach USD 1.42 billion in 2026 and grow at a CAGR of 10.86% to USD 2.67 billion by 2032
Merck's CAPVAXIVE Added To Ontario's Publicly Funded Adult Immunization Program
Merck (NYSE:MRK), known as MSD outside the United States and Canada, welcomes Ontario's decision to include CAPVAXIVE® in its publicly funded adult immunization program. This addition helps expand access to
MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data
Laidlaw analyst Yale Jen flagged possible data in other cancers from 2027, while warning that personalized manufacturing costs, capacity and reimbursement could limit commercial success.
Merck Signs Exclusive Global License Agreement With SciBrunch Therapeutics For SPR2015, An Investigational Preclinical Oral KRAS G12D Inhibitor, For $400M Up Front Plus Payments; Company To Record Pre-Tax Charge Of $0.13 Per Share In Q3
Under the agreement, SciBrunch has granted Merck exclusive rights to develop, manufacture and commercialize SPR2015 worldwide. SciBrunch will receive an upfront payment of $400 million and is eligible to receive
United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy
United Therapeutics' declines are real but they sit in ~32% of the business, tax-normalized earnings power is $1.05 billion. See why UTHR stock is a Buy now.
Earn 10-15% Potential Income: Monthly Options Series (Oct. 2026)
Build a disciplined options income strategy targeting 12â15% annually. Read the full analysis here.
Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks
In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026 and accompanied by growing oncology-focused pipeline visibility. At the same time, Moderna’s talks with Middle East partners about potential investment and manufacturing cooperation highlight how its mRNA...
Merck Is Up 40% This Year, but Is the Keytruda Rebuild Already Priced In?
Key Stats for Merck Stock52-Week Range: $78 to $157Market Cap: around $367 billionStreet Mean Target: around $154Forward 2-Year Revenue Growth (CAGR): around 4%NTM EV/EBITDA: around 17xLTM Gross Margin: 75. 9%Dividend Yield: 2.
Merck (MRK) Stock May Be 37% Undervalued On Fresh FDA Approval
Merck’s stock has had a strong multi year run, and with the shares closing at US$148.78 most recently, the key question for you is whether that level is supported by the cash the business can generate over time. Over the past 5 years, Merck has delivered a total return of 113.0%, which puts real weight on the question of whether the current valuation still lines up with its underlying cash flows. Recent approvals and label expansions for treatments such as Welireg combinations, WINREVAIR and...
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
RAHWAY, N.J., September 25, 2026--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn.
Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years
Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 3.0% on an annualized basis producing an average annual return of 15.2%. Currently, Merck & Co has a market capitalization of $364.51
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.
Friday's session: top gainers and losers in the dow jones index
Curious about the dow jones stocks that are in motion on Friday? Join us as we explore the top movers within the dow jones index during today's session.
Merck, Daiichi Sankyo Voluntarily Withdraw Biologics License Application Approval In U.S. For Ifinatamab Deruxtecan To Treat Small Cell Lung Cancer After Discussions With FDA
The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan
AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street
AMD crossed $1 trillion and Meta's Muse rattled subscription stocks. Meanwhile, Treasury yields hit 2007 highs.
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
How To Build A $75,000 Dividend Portfolio With SCHD And 5 High-Yield Picks
Build a $75K dividend portfolio anchored by SCHD, enhanced with JEPI, VNG, and 8 quality stocks to boost yield, growth, and diversificationâread now.
Merck remigromig DME trial results raise safety concerns
Remigromig matched a standard treatment for diabetic macular edema in a late-stage study, but showed higher rates of certain retinal complications
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
RAHWAY, N.J. & NUTLEY, N.J., September 25, 2026--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component
U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), the
Bank of America has strong message for Merck stock investors
A private meeting with the drugmaker’s top doctor points to the next make-or-break moment for shareholders.
Why is Moderna (MRNA) Stock Trending After Hours?
Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.
Merck Jumps as Winrevair Moves Earlier in PAH
The label now includes evidence from newly diagnosed patients, widening confidence before revealing commercial uptake.
Stay informed with the top movers within the dow jones index on Thursday.
Curious about the top performers within the dow jones index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.
These Dow Jones Stocks Buck Index's Dud Performance
Some consumer, technology and industrial components form a solid core of possibilities for investors.
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
Merck & Co. Inc. (NYSE:MRK) on Thursday announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). DME is a serious eye complication of diabetes where high blood sugar damages tiny retinal blood vessels, causing them to leak fluid into the macula (the central part of the retina responsible for sharp vision) and making it swell. BRUNELLO is the first of two Phase 2b/3 trials evaluating remigromig (MK-3000, formerly EYE103), an investigational
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention. Its experimental cancer drug INBRX-106, combined with Merck’s Keytruda, produced a confirmed response rate nearly twice that of Keytruda alone in a Phase 2 head and neck cancer study. The results were even stronger among a […]
Thursday's session: top gainers and losers in the dow jones index
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding
Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper than most investors expect.
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
Merck reveals study success, and possible safety worries, for eye drug hopeful
A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.
FDA Approves Merck's Belzutifan With Lenvatinib For Advanced Kidney Cancer With Clear Cell Component
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component
Trebellar Raises $18M Series A to Bring AI to Corporate Real Estate Management
SAN FRANCISCO, September 24, 2026--Trebellar, a company building AI-native decision making for corporate real estate management, today announced $18 million in Series A funding led by Blossom Capital, with participation from Haystack, Alt Capital, 1Flourish, and Bynd. The investment reflects growing enterprise demand and investor confidence that corporate real estate, one of the last major back-office functions without dedicated software, is the next to modernize.
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
Merck (MRK), What Is Behind The Fresh Attention Now?
Merck (MRK) just secured an FDA label update for WINREVAIR in pulmonary arterial hypertension, adding detailed Phase 3 HYPERION trial data that clarifies benefits, risks and real-world treatment conditions for this relatively new therapy. Merck’s recent FDA label update for WINREVAIR lands while the share price has climbed strongly over 2026, with a 90-day share price return of 18.04%, a year-to-date gain of 39.11%, and a 1-year total shareholder return of 91.32%, suggesting momentum has been...
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.
Alpha Buying: Follow the Money From NVIDIA and Merck
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the investment portfolios of
You Only Need $2,000 and 1 Fund to Start Building a Dividend Portfolio. Here’s the ETF to Use
Most beginners chase the highest yield they can find and end up owning a ticking time bomb. One fund built around a completely different logic has quietly turned $2,000 starting positions into compounding income machines for over a decade.
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
RAHWAY, N.J., September 24, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pa
Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of
Merck (MRK) Declines More Than Market: Some Information for Investors
In the latest trading session, Merck (MRK) closed at $148.08, marking a -1.88% move from the previous day.
Wednesday's session: top gainers and losers in the dow jones index
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Wednesday.
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.
Merck pipeline seen driving potential re-rating as clinical catalysts approach
Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with...
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.
Merck Manuals Details What Patients Need to Know About Inflammatory Bowel Disease
When patients experience prolonged diarrhea and abdominal pain, one condition doctors may consider is inflammatory bowel disease (IBD). In IBD, different parts of the gastrointestinal tract become inflamed, often causing recurring abdominal pain and diarrhea. If left untreated, the inflammation from IBD can lead to serious complications.
3 Healthcare Stocks with Warning Signs
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 38.9% over the past six months, topping the S&P 500 by 20.9 percentage points.
Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue
Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Therapy (BT) Designation - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Breakthrough Therapy (BT) Designation was estimated at US$79.7 Billion in 2025 and is projected to reach US$212.5 Billion by 2032, growing at a C
Merck's Melt-Up Triggers Profit-Taking Risks - Multi-Year Portfolio Renewal (Rating Downgrade)
Lipfendra and promising intismeran autogene trial results support Merck's multi-year portfolio renewal prospects amid patent cliff risks. Read why MRK is a Hold.
Tuesday's session: top gainers and losers in the dow jones index
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.
3 Reasons to Sell MRK and 1 Stock to Buy Instead
Over the past six months, Merck has been a great trade, beating the S&P 500 by 13.4%. Its stock price has climbed to $149.98, representing a healthy 29.6% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.
Why Is Merck (MRK) In Focus After Japan Cleared A New Dosing Option?
Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX (KEYJECT), its first subcutaneous KEYTRUDA formulation, for all existing local indications. The new subcutaneous version offers an alternative to intravenous dosing, aimed at faster administration for patients and clinicians. This approval broadens Merck's oncology treatment options in Japan, a key international market for its immunotherapy portfolio. The KEYTRUDA QLEX subcutaneous green light in Japan matters. However, investors...
U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
RAHWAY, N.J., September 22, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. WINREVAIR, an activin signaling inhibitor, is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade
Meta's agentic AI assistant Muse lit a fire under tech on Monday, pushing the Nasdaq to a record close and lifting chipmakers by double digits. Cheaper oil, a ten-year yield back below 5% and a friendlier tone between Washington and Beijing did the rest, while Paramount cleared the last big hurdle for its Warner Bros. Discovery takeover.
Merck Says FDA Approves Update To US Product Label For WINREVAIR For Injection, 45mg, 60mg, Based On The Phase 3 HYPERION Trial
In HYPERION, in patients diagnosed with PAH in the last 12 months, adding WINREVAIR on top of background therapy reduced the risk of clinical worsening events compared to placebo, informing the use of WINREVAIR earlier
Novo defends diversification push as CEO eyes deals beyond obesity
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
Moderna (MRNA) Stock Trades Up, Here Is Why
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum.
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost
Stock Market Today: Nasdaq Roars As Micron Tests Entry; AMD In Buy Zone As It Eyes New High (Live Coverage)
The Dow Jones index rallies on the stock market today after Treasury Secretary Scott Bessent touts China talks. Nvidia stock climbs.
Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’
Moderna will showcase detailed melanoma results for Intismeran at ESMO, alongside data and trial updates exploring the personalized therapy in pancreatic and lung cancers.
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.
Discover which dow jones stocks are making waves on Monday.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors
Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Moderna (NASDAQ:MRNA) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at the European Society for Medical Oncology congress in Madrid. The stock is at $167.90, up 9% in Monday morning […]
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations
Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies
AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.
What Would It Take For Pfizer To Cut Its Dividend?
Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is proud to be the presenting partner of Chiharu Shiota: The Soul Trembles, a landmark contemporary art exhibition making its North American premiere at the Montreal Museum of Fine Arts (MMFA) from September 26, 2026, to February 14, 2027.
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.
Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
RAHWAY, N.J., September 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administer
Merck's Subcutaneous KEYTRUDA QLEX Approved In Japan For All Existing KEYTRUDA Indications
KEYTRUDA QLEX is the first and only subcutaneous immune checkpoint inhibitor in Japan that can be administered by a healthcare provider in as little as one minuteMerck (NYSE:MRK), known as MSD outside of the United
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations. The answer may surprise investors who have been watching Merck's blockbuster momentum.
The Next Big Theme: September 2026
Data center construction spending increased nearly 60% YoY in July 2026 to surpass a $75 billion annualized pace as AI translates into a major U.S. construction cycle. Read more here.
The S&P 500 Has Returned About 11% Annually Since 1958. Here's the ETF I'd Trust for the Next 30 Years.
Investors need something that evolves with a changing economy.
What Does Merck (MRK) Mean For EU Bladder Cancer Treatment After CHMP Support?
Merck (NYSE:MRK) received a positive opinion from the EMA’s CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The CHMP verdict on KEYTRUDA plus Padcev is only one piece of the wider Merck story...
What Would It Take For Eli Lilly Stock To Keep Climbing?
Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.
Is Johnson & Johnson Stock Expensive, Or Is STELARA Hiding The Real Price?
Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.
Merck Stock Nearly Doubled Without A Change In Its Revenue Growth
Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.
Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?
Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income
A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
RAHWAY, N.J., September 18, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invas
Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
RAHWAY, N.J., September 18, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today launched Your Hive of Whole Health, a multi-year educational program that helps people living with HIV build personalized networks of support to address their physical, mental, emotional, and social well-being. Unveiled at the 2026 U.S. Conference on HIV/AIDS (USCHA) in Anaheim, California, Sept. 17-20, 2026, the initiative aims to honor the strides made toward ending the epidemic whi
Veradermics: Buy Before The Catalysts
Veradermics (MANE) stock outlook: Phase 3 VDPHL01 readouts, FDA approval odds, cash runway, and hair loss market upsideâsee the bull case and act now.
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.
The Hidden Winners Inside SCHD - September 2026
Schwab US Dividend Equity ETF (SCHD) has outperformed SPY year-to-date, widening its lead during recent market volatility.
EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
Opinion granted based on positive results from the Phase 3 KEYNOTE-B15 trial, which demonstrated improvements in event-free survival, overall survival and pathologic complete response rateIf approved, KEYTRUDA plus
Merck (MRK) Outperforms Broader Market: What You Need to Know
Merck (MRK) closed at $147.17 in the latest trading session, marking a +1.56% move from the prior day.
Merck Gains as Keytruda's Space Research Seeks a New Home
Commercial orbital laboratories could extend proven microgravity research, but regulation and return logistics remain unresolved.
Can Volume Keep Covering Eli Lilly's Price Cuts?
Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.
Discover which dow jones stocks are making waves on Thursday.
Curious about the top performers within the dow jones index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Moderna: Another Day, Another Big Stock Move. Is the Cancer Vaccine Rally Back On?
Moderna President Stephen Hoge says the company remains on track for its longtime goal of reaching cash breakeven by 2028.
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.
Moderna Stock Is Surging: What's Going On?
Moderna Inc. (NASDAQ: MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
Moderna stock has more than doubled after its cancer-vaccine breakthrough. Now investors face the harder question: Can it become an oncology powerhouse?
What Happens To AbbVie Stock If SKYRIZI Slows Down?
AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.
Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise
Auxier Asset Management, an investment advisory firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. Following a strong rebound from the first-quarter decline, the S&P 500 gained 15.2% as accelerating capital spending toward artificial intelligence infrastructure drove significant gains across technology hardware companies. Semiconductor and data-center-related businesses benefited from supply constraints […]
5 Wealth-Building Stocks to Buy With an Inheritance, So You Have Something to Leave Your Kids, Too
With $124 trillion set to move in the Great Wealth Transfer, these wealth-building stocks can help you leave something behind for your kids.
Is Pfizer's New Business Big Enough To Carry The Old One?
Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Directors (the “Board”). Dr. Meyer most recently served as Princi
Should You Judge JNJ Stock Without STELARA?
Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points. Management is encouraging investors to evaluate the company's underlying momentum by presenting growth rates that exclude STELARA alongside its reported figures.
AstraZeneca Shares Rise as J.P. Morgan Stays Overweight
The bank's peak sales estimate for laroprovstat sits 30% above consensus
This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%
Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.
Novo Nordisk, Anthropic Team Up For AI Drug Research
Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement responsible data governance standards.
Oncology Tie-Up and Blockchain Pilot Might Change The Case For Investing In Merck (MRK)
In early September 2026, Merck & Co., Inc. deepened its innovation push through multiple investor conferences and a new clinical trial collaboration in which Perspective Therapeutics announced it will test its targeted alpha therapy [212Pb]PSV359 with Merck’s immunotherapy Keytruda in certain FAP-a–expressing lung and colorectal cancers. At the same time, Merck partnered with The Hashgraph Group and PwC Germany on a cocoa traceability pilot that links its M-Trust physical authentication...
Merck Stock: Is The $70 Billion Pipeline Worth the Premium?
A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.
Discover which dow jones stocks are making waves on Tuesday.
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Tuesday.
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next growth phase?
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
Slate Medicines Names Kenneth Koblan as Chief Scientific Officer
By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief Scientific Officer and Head of Development Operations. Dr. Koblan is a biopharmaceutical R&D leader with more than 30 years […] The post Slate Medicines Names Kenneth Koblan as Chief Scientific Officer appeared first on ExecEdge.
Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030
Eli Lilly and Merck both reported second quarter earnings, and the contrast could not be sharper. One company is compounding a franchise that keeps widening, while the other is racing to patch a hole before a patent cliff arrives.
Merck & Co Inc's Dividend Analysis
Merck & Co Inc (NYSE:MRK) recently announced a total dividend of $0.85 per share, with the ex-dividend date set for 2026-09-15. This amount includes a $0.85 per share cash dividend payable on 2026-10-07. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.
GSK to Acquire Experimental Blood Cancer Therapy From Chimagen in $750 Million Deal
GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple mye
These 3 Income-Oriented ETFs Are All You Need For Retirement
Retirement income update: Why the 4% rule can fail in todayâs market and how a yield-first ETF mix may pay ~$48k/$1M. Read the full analysis here.
Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation
Merck & Co., Inc. (NYSE:MRK) Chairman and CEO Rob Davis said the company’s “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its Animal Health segment during a Morgan Stanley discussion. Davis said recent pipeline readouts ha
Is This LLY Stock Dip Big Enough To Be Worth Buying?
Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.
Why Is Pfizer Stock Paying You So Much To Wait?
Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management's answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.
Merck & Co., Inc. (MRK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Merck & Co., Inc. (MRK) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 3:20 PM EDTCompany ParticipantsRobert Davis -...
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
Merck & Co Exec Says Timing For Raising The $70B Forecast Is "To Be Determined" Adds "It's Coming"
https://www.merck.com/events/morgan-stanley-24th-annual-global-healthcare-conference/
Merck Exec Speaking At Morgan Stanley Conference Says Potential 340B And Policy Changes Would Create Tailwinds But Are Not Material To The Business
https://www.merck.com/events/morgan-stanley-24th-annual-global-healthcare-conference/
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types. Speaking at a Morgan Stanley ev
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.
Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve
Eli Lilly shed billions in market value over the past month while its underlying business kept breaking records, and now one major Wall Street firm sees a setup that almost never appears in a stock this dominant.
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in com
Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock
Discussing his fantasy roster on the September 8 episode of Mad Money, Jim Cramer turned his focus to pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) to support his defense and special teams unit, as he remarked: Beyond the offense, there’s a spot on your roster for something called a defense/special teams pick in fantasy football. […]
2 Outstanding Dividend Stocks to Buy and Hold for 10 Years
Income seekers can't go wrong with these companies.
Is AbbVie Stock Actually Overpriced?
AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.
Dividend Champion, Contender, And Challenger Highlights: Week September 13
Read this week's dividend recap for Dividend Champions, Contenders & Challengersâtrack dividend changes, upcoming ex-dividend dates & pay dates.
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat
Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
IHE: Innovation Supports The Outlook, Valuation Limits Conviction
IHE trades at a P/E of 16.11x and is rated HOLD due to regulatory, patent, and concentration risks. Click for more details on the IHE fund.
Advanced Bioreactor Systems Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
The global Advanced Bioreactor Systems Market is projected to grow from USD 4.2 billion in 2026 to USD 11.8 billion by 2036, at a CAGR of 10.9%. Growth is driven by biologics manufacturing, cell and gene therapies, single-use bioreactors, continuous bioprocessing, and AI-based process control. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes market segments, regional opportunities, technology trends, and key companies including Sartorius, Thermo
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
Merck builds around Keytruda; prediction markets raise new risks
Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.
Merck (MRK) Dips More Than Broader Market: What You Should Know
In the most recent trading session, Merck (MRK) closed at $144.71, indicating a -1.91% shift from the previous trading day.
Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?
In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.
Which dow jones stocks are moving on Thursday?
Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions
A congresswoman recently bought stocks connected to Warren Buffett and Elon Musk.
JNJ Stock: Is the Rally Running Out of Steam?
A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Seidman Christine E | +56 | $145.31 | $8,137 |
| 2026-09-30 | Karsanbhai Surendralal Lanca | +112 | $145.31 | $16,275 |
| 2026-09-30 | Coe Mary Ellen | +206 | $145.31 | $29,934 |
| 2026-08-13 | Guindo Chirfi | -10,000 | $135 | $1,350,000 |
| 2026-08-12 | Zachary Jennifer | -13,433 | - | - |
| 2026-08-12 | Zachary Jennifer | -41,494 | - | - |
| 2026-08-12 | Zachary Jennifer | -80,315 | $133.4557 | $10,718,495 |
| 2026-08-12 | Zachary Jennifer | +13,433 | $84.71 | $1,137,909 |
| 2026-08-12 | Zachary Jennifer | +41,494 | $117.89 | $4,891,728 |
| 2026-08-12 | DeLuca Richard R. | -600 | $132.0367 | $79,222 |
| 2026-08-12 | DeLuca Richard R. | -11,099 | $131.6128 | $1,460,770 |
| 2026-08-11 | DeLuca Richard R. | -5,427 | $132.3496 | $718,261 |
| 2026-08-11 | DeLuca Richard R. | -7,410 | $131.3313 | $973,165 |
| 2026-08-10 | DeLuca Richard R. | -20,784 | $130.4345 | $2,710,951 |
| 2026-08-06 | Guindo Chirfi | -15,000 | $131 | $1,965,000 |
| 2026-08-06 | DeLuca Richard R. | -300 | $131.0233 | $39,307 |
| 2026-08-06 | DeLuca Richard R. | -4,945 | $130.2312 | $643,993 |
| 2026-08-06 | DeLuca Richard R. | -805 | $131.0216 | $105,472 |
| 2026-08-05 | Maraldo David R. | -2,686 | - | - |
| 2026-08-05 | Maraldo David R. | -9,709 | - | - |
| 2026-08-05 | Maraldo David R. | -6,311 | - | - |
| 2026-08-05 | Maraldo David R. | -2,686 | $128.7179 | $345,736 |
| 2026-08-05 | Maraldo David R. | +2,686 | $84.71 | $227,531 |
| 2026-08-05 | Maraldo David R. | -9,709 | $128.7179 | $1,249,722 |
| 2026-08-05 | Maraldo David R. | +9,709 | $87.1 | $845,654 |
| 2026-08-05 | Maraldo David R. | -6,311 | $128.7179 | $812,339 |
| 2026-08-05 | Maraldo David R. | +6,311 | $73.73 | $465,310 |
| 2026-08-05 | Williams David Michael | -34,705 | - | - |
| 2026-08-05 | Williams David Michael | -13,542 | - | - |
| 2026-08-05 | Williams David Michael | -4,600 | - | - |
| 2026-08-05 | Williams David Michael | -34,705 | $128.7707 | $4,468,987 |
| 2026-08-05 | Williams David Michael | +34,705 | $73.73 | $2,558,800 |
| 2026-08-05 | Williams David Michael | -13,542 | $128.7707 | $1,743,813 |
| 2026-08-05 | Williams David Michael | +13,542 | $75.36 | $1,020,525 |
| 2026-08-05 | Williams David Michael | -4,600 | $128.7707 | $592,345 |
| 2026-08-05 | Williams David Michael | +4,600 | $77.62 | $357,052 |
| 2026-06-30 | Seidman Christine E | +63 | $128.5 | $8,096 |
| 2026-06-30 | Karsanbhai Surendralal Lanca | +126 | $128.5 | $16,191 |
| 2026-06-30 | Coe Mary Ellen | +233 | $128.5 | $29,941 |
| 2026-05-29 | Mayo Stephen | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | Seidman Christine E | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | Karsanbhai Surendralal Lanca | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | Coe Mary Ellen | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | Rothman Paul | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | Warden Kathy J | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | THULIN INGE G | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | Craig Pamela J. | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | BAKER DOUGLAS M JR | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | GLOCER THOMAS H | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | LAVIZZO-MOUREY RISA J | +1,853 | $118.72 | $219,988 |
| 2026-05-29 | RUSSO PATRICIA F | +1,853 | $118.72 | $219,988 |
| 2026-05-05 | Maraldo David R. | +21,731 | - | - |
| 2026-05-05 | Maraldo David R. | +7,424 | - | - |
| 2026-05-05 | Foard Brian | +31,044 | - | - |
| 2026-05-05 | Foard Brian | +35,351 | - | - |
| 2026-05-05 | Foard Brian | +10,605 | - | - |
| 2026-05-05 | Smart Dalton E. III | +5,045 | - | - |
| 2026-05-05 | Smart Dalton E. III | +2,298 | - | - |
| 2026-05-05 | Oosthuizen Johannes Jacobus | +31,044 | - | - |
| 2026-05-05 | Oosthuizen Johannes Jacobus | +10,605 | - | - |
| 2026-05-05 | Litchfield Caroline | +46,566 | - | - |
| 2026-05-05 | Litchfield Caroline | +15,908 | - | - |
| 2026-05-05 | Li Dean Y | +58,207 | - | - |
| 2026-05-05 | Li Dean Y | +19,885 | - | - |
| 2026-05-05 | Williams David Michael | +13,582 | - | - |
| 2026-05-05 | Williams David Michael | +4,640 | - | - |
| 2026-05-05 | Zachary Jennifer | +35,312 | - | - |
| 2026-05-05 | Zachary Jennifer | +12,064 | - | - |
| 2026-05-05 | Guindo Chirfi | +19,402 | - | - |
| 2026-05-05 | Guindo Chirfi | +6,628 | - | - |
| 2026-05-05 | Larson Betty D | +23,283 | - | - |
| 2026-05-05 | Larson Betty D | +7,954 | - | - |
| 2026-05-05 | DeLuca Richard R. | +34,924 | - | - |
| 2026-05-05 | DeLuca Richard R. | +11,931 | - | - |
| 2026-05-05 | Davis Robert M | +139,697 | - | - |
| 2026-05-05 | Davis Robert M | +47,724 | - | - |
| 2026-05-02 | Maraldo David R. | -552 | - | - |
| 2026-05-02 | Maraldo David R. | -159 | $112.16 | $17,833 |
| 2026-05-02 | Maraldo David R. | +552 | $112.16 | $61,912 |
| 2026-05-02 | Smart Dalton E. III | -383 | - | - |
| 2026-05-02 | Smart Dalton E. III | -132 | $112.16 | $14,805 |
| 2026-05-02 | Smart Dalton E. III | +383 | $112.16 | $42,957 |
| 2026-04-30 | Smart Dalton E. III | -464 | - | - |
| 2026-04-30 | Smart Dalton E. III | -159 | $110.95 | $17,641 |
| 2026-04-30 | Smart Dalton E. III | +464 | $110.95 | $51,481 |
| 2026-04-30 | Larson Betty D | -11,350 | - | - |
| 2026-04-30 | Larson Betty D | -5,143 | $110.95 | $570,616 |
| 2026-04-30 | Larson Betty D | +11,350 | $110.95 | $1,259,283 |
| 2026-04-29 | Smart Dalton E. III | -944 | - | - |
| 2026-04-29 | Smart Dalton E. III | -324 | $110.03 | $35,650 |
| 2026-04-29 | Smart Dalton E. III | +944 | $110.03 | $103,868 |
| 2026-04-29 | Oosthuizen Johannes Jacobus | -1,377 | - | - |
| 2026-04-29 | Oosthuizen Johannes Jacobus | -679 | $110.03 | $74,710 |
| 2026-04-29 | Oosthuizen Johannes Jacobus | +1,377 | $110.03 | $151,511 |
| 2026-04-29 | Litchfield Caroline | -3,935 | - | - |
| 2026-04-29 | Litchfield Caroline | -1,938 | $110.03 | $213,238 |
| 2026-04-29 | Litchfield Caroline | +3,935 | $110.03 | $432,968 |
| 2026-04-29 | Li Dean Y | -4,722 | - | - |
| 2026-04-29 | Li Dean Y | -2,326 | $110.03 | $255,930 |
| 2026-04-29 | Li Dean Y | +4,722 | $110.03 | $519,562 |
| 2026-04-29 | Williams David Michael | -1,377 | - | - |
| 2026-04-29 | Williams David Michael | -679 | $110.03 | $74,710 |
| 2026-04-29 | Williams David Michael | +1,377 | $110.03 | $151,511 |
| 2026-04-29 | Zachary Jennifer | -2,951 | - | - |
| 2026-04-29 | Zachary Jennifer | -1,454 | $110.03 | $159,984 |
| 2026-04-29 | Zachary Jennifer | +2,951 | $110.03 | $324,699 |
| 2026-04-29 | Guindo Chirfi | -1,967 | - | - |
| 2026-04-29 | Guindo Chirfi | -969 | $110.03 | $106,619 |
| 2026-04-29 | Guindo Chirfi | +1,967 | $110.03 | $216,429 |
| 2026-04-29 | Chattopadhyay Sanat | -2,597 | - | - |
| 2026-04-29 | Chattopadhyay Sanat | -1,130 | $110.03 | $124,334 |
| 2026-04-29 | Chattopadhyay Sanat | +2,597 | $110.03 | $285,748 |
| 2026-04-29 | Larson Betty D | -2,085 | - | - |
| 2026-04-29 | Larson Betty D | -715 | $110.03 | $78,671 |
| 2026-04-29 | Larson Betty D | +2,085 | $110.03 | $229,413 |
| 2026-04-29 | DeLuca Richard R. | -2,518 | - | - |
| 2026-04-29 | DeLuca Richard R. | -1,241 | $110.03 | $136,547 |
| 2026-04-29 | DeLuca Richard R. | +2,518 | $110.03 | $277,056 |
| 2026-04-29 | Davis Robert M | -13,300 | - | - |
| 2026-04-29 | Davis Robert M | -6,551 | $110.03 | $720,807 |
| 2026-04-29 | Davis Robert M | +13,300 | $110.03 | $1,463,399 |
| 2026-03-31 | Seidman Christine E | +68 | $120.29 | $8,180 |
| 2026-03-31 | Coe Mary Ellen | +249 | $120.29 | $29,952 |
| 2026-03-31 | GLOCER THOMAS H | +405 | $120.29 | $48,717 |
| 2026-02-12 | Guindo Chirfi | -10,000 | $121.4562 | $1,214,562 |
| 2026-02-10 | Li Dean Y | -10,235 | $117.5226 | $1,202,844 |
| 2026-02-09 | Zachary Jennifer | -38,835 | - | - |
| 2026-02-09 | Zachary Jennifer | -56,792 | - | - |
| 2026-02-09 | Zachary Jennifer | -25,946 | - | - |
| 2026-02-09 | Zachary Jennifer | -38,835 | $119.1522 | $4,627,276 |
| 2026-02-09 | Zachary Jennifer | +38,835 | $119.1522 | $4,627,276 |
| 2026-02-09 | Zachary Jennifer | -56,792 | $119.1522 | $6,766,892 |
| 2026-02-09 | Zachary Jennifer | +56,792 | $119.1522 | $6,766,892 |
| 2026-02-09 | Zachary Jennifer | -25,946 | $119.1522 | $3,091,523 |
| 2026-02-09 | Zachary Jennifer | +25,946 | $119.1522 | $3,091,523 |
| 2026-02-09 | Guindo Chirfi | -10,000 | $118.4101 | $1,184,101 |
| 2026-02-06 | Oosthuizen Johannes Jacobus | -15,000 | $121.8661 | $1,827,992 |
| 2026-02-06 | Williams David Michael | -5,000 | - | - |
| 2026-02-06 | Williams David Michael | -5,000 | $121.905 | $609,525 |
| 2026-02-06 | Williams David Michael | +5,000 | $77.62 | $388,100 |
| 2026-02-06 | DeLuca Richard R. | -37,685 | $120.9241 | $4,557,025 |
| 2026-02-05 | Guindo Chirfi | -20,000 | $121.8838 | $2,437,676 |
| 2026-02-04 | Smart Dalton E. III | -4,000 | - | - |
| 2026-02-04 | Smart Dalton E. III | -2,400 | $119.675 | $287,220 |
| 2026-02-04 | Smart Dalton E. III | -4,000 | $119.675 | $478,700 |
| 2026-02-04 | Smart Dalton E. III | +4,000 | $62.07 | $248,280 |
| 2026-02-04 | Litchfield Caroline | -41,997 | - | - |
| 2026-02-04 | Litchfield Caroline | -41,997 | $119.6112 | $5,023,312 |
| 2026-02-04 | Litchfield Caroline | +41,997 | $53.06 | $2,228,361 |
| 2026-02-04 | Li Dean Y | -15,087 | - | - |
| 2026-02-04 | Li Dean Y | -15,087 | $118.7661 | $1,791,824 |
| 2026-02-04 | Li Dean Y | +15,087 | $56.04 | $845,475 |
| 2026-02-04 | Davis Robert M | -32,462 | $118.3513 | $3,841,920 |
| 2026-02-04 | Davis Robert M | -14,972 | $117.3796 | $1,757,407 |
| 2026-01-26 | Smart Dalton E. III | +1,066 | $107.4 | $114,488 |
| 2026-01-26 | Romanelli Joseph | +5,703 | $107.4 | $612,502 |
| 2026-01-26 | Oosthuizen Johannes Jacobus | +5,026 | $107.4 | $539,792 |
| 2026-01-26 | Litchfield Caroline | +15,852 | $107.4 | $1,702,505 |
| 2026-01-26 | Li Dean Y | +20,469 | $107.4 | $2,198,371 |
| 2026-01-26 | Williams David Michael | +6,112 | $107.4 | $656,429 |
| 2026-01-26 | Zachary Jennifer | +11,583 | $107.4 | $1,244,014 |
| 2026-01-26 | Guindo Chirfi | +9,865 | $107.4 | $1,059,501 |
| 2026-01-26 | Chattopadhyay Sanat | +13,880 | $107.4 | $1,490,712 |
| 2026-01-26 | DeLuca Richard R. | +12,264 | $107.4 | $1,317,154 |
| 2026-01-26 | Davis Robert M | +47,434 | $107.4 | $5,094,412 |
| 2025-12-31 | Seidman Christine E | +77 | $105.26 | $8,105 |
| 2025-12-31 | Coe Mary Ellen | +285 | $105.26 | $29,999 |
| 2025-12-31 | GLOCER THOMAS H | +463 | $105.26 | $48,735 |
| 2025-11-10 | Downing Cristal N | -7,085 | $87 | $616,395 |
| 2025-11-03 | Williams David Michael | -8,614 | $83.5895 | $720,040 |